A Phase 2/3 clinical trial is again recruiting participants to continue investigating the immunomodulator Leukine (sargramostim) in combination with checkpoint inhibitors Yervoy (ipilimumab) and Opdivo (nivolumab) as an initial treatment for patients with melanoma. The decision to resume enrollment follows positive — but as yet, undisclosed — safety and survival results from the first 250 patients included in the EA6141 trial (NCT02339571). After a go-ahead from a Data Safety Monitoring Committee, the Phase 3 part…
You must be logged in to read/download the full post.
The post Enrollment Underway in Melanoma Trial Testing Leukine Triple Combo appeared first on BioNewsFeeds.